Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Abbott Receives CE Mark for Alinity Molecular Diagnostics System, Assays

Abbott Receives CE Mark for Alinity Molecular Diagnostics System, Assays

Mar 19, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Abbott announced today that it has received CE marking for its Alinity m molecular diagnostics system and assays, which are now available in countries that recognize the designation.

The firm said that its molecular system will help clinicians who are struggling to keep up with demand for infectious disease testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Pro-Lab Diagnostics Nabs FDA Emergency Use Authorization for Molecular SARS-CoV-2 Test

  2. FDA Sends Warning Letters About Unauthorized SARS-CoV-2 Tests

  3. Biomeme, LumiraDx PCR Coronavirus Tests Get FDA Emergency Use Authorization

  4. BioMérieux, Beijing Wantai Coronavirus Antibody Tests Get FDA Emergency Use Authorization

  5. Solaris Diagnostics, Alpha Genomix Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.